natgillin/translations-raw huggingface dataset:
Combivir does not cure HIV infection or AIDS, but it may hold off damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo Combivir ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
Children taking Combivir should be closely monitored and the doctor may need to adjust the dose in case of side effects on their digestive system. 
Otroke, ki prejemajo zdravilo Combivir, je treba skrbno spremljati, zdravnik pa bo morda moral v primeru pojava neželenih učinkov v prebavnem sistemu odmerek ustrezno prilagoditi.
The studies showed that the active substances taken together could reduce viral loads (the level of HIV in the blood) and allow CD4 cell counts to rise after up to one year of treatment. 
Te študije so pokazale, da lahko jemanje obeh učinkovin skupaj zmanjša virusno breme (količino virusa HIV v krvi) in spodbudi zvišanje števila celic CD4 po enem letu zdravljenja.
The recommended doses of Combivir in children produced similar levels of the two active substances as in older patients. 
Priporočeni odmerki zdravila Combivir pri otrocih povzročajo podobne ravni obeh zdravilnih učinkovin kot pri starejših bolnikih.
Treatment with Combivir should be started by a doctor who has experience in the management of HIV infection. 
Zdravljenje z zdravilom Combivir lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Combivir, an antiviral medicine, is used in combination with at least one other antiviral medicine to treat patients infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS). 
Zdravilo Combivir je protivirusno zdravilo, ki se uporablja v kombinaciji z vsaj enim drugim protivirusnim zdravilom za zdravljenje bolnikov, okuženih z virusom humane imunske pomanjkljivosti (HIV), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
For practical information about using Combivir, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Combivir naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Both active substances in Combivir, lamivudine and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs). 
Obe zdravilni učinkovini v zdravilu Combivir, lamivudin in zidovudin, sta zaviralca nukleozidne reverzne transkriptaze (NRTI).
The most common side effects with Combivir (which may affect more than 1 patient in 10) are diarrhoea and nausea (feeling sick). 
Najpogostejša neželena učinka zdravila Combivir (opažena pri več kot 1 bolniku od 10) sta driska in navzeja (slabost).
The two groups also had similar rises in CD4 cell counts. 
V obeh skupinah bolnikov je bilo zvišanje števila celic CD4 podobno.
To support its recommendations for Combivir doses in children, the company presented studies of the levels of lamivudine and zidovudine in the blood of children taking the medicines separately. 
Družba je v podporo svojim priporočenim odmerkom zdravila Combivir pri otrocih predstavila študije ravni lamivudina in zidovudina v krvi otrok, ki so obe učinkovini jemali ločeno.
CHMP considered that combining the active ingredients in a single tablet may be of advantage because it can improve how well patients stick to the prescribed treatment and this can help to prevent HIV becoming resistant to treatment. 
Menil je, da bi lahko bila združitev obeh zdravilnih učinkovin v eni tableti koristna, ker bolnike spodbuja k temu, da vztrajajo pri predpisanem zdravljenju, to pa posledično pripomore k preprečevanju razvoja odpornosti virusa HIV proti zdravilu.
Combivir was absorbed in the same way as the separate tablets. 
Bolniki so zdravilo Combivir absorbirali enako kot ločeni tableti.
For the full list of all the side effects of Combivir and restrictions on its use, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev, o katerih so poročali pri uporabi zdravila Combivir, glejte navodilo za uporabo.
Patients taking Combivir and those taking the two active substances separately had similar falls in viral load. 
Pri bolnikih, ki so jemali zdravilo Combivir, in tistih, ki so jemali obe zdravilni učinkovini v ločenih tabletah, je prišlo do podobnega znižanja virusnega bremena.
How is Combivir used? 
Kako se zdravilo Combivir uporablja?
Combivir contains two active substances, lamivudine and zidovudine. 
Zdravilo Combivir vsebuje dve zdravilni učinkovini, lamivudin in zidovudin.
How does Combivir work? 
Kako zdravilo Combivir deluje?
The studies indicated that 1,8 cineole might have an effect in diseases of the airways. 
Študije so pokazale, da lahko 1,8 cineol vpliva na bolezni dihalnih poti.
If symptoms persist for longer than a week, a doctor should be consulted. 
Če simptomi po enem tednu ne izginejo, se je treba posvetovati z zdravnikom.
At the time of the HMPC assessment, no side effects had been reported with these medicines when used in the way described above. 
V času ocene odbora HMPC ni bilo poročil o neželenih učinkih teh zdravil pri njihovi uporabi na zgoraj navedeni način.
Eucalyptus leaf is the common name for the whole or cut leaf of the tree Eucalyptus globulus Labill. 
List evkaliptusa je splošno ime za cel ali narezan list drevesa Eucalyptus globulus Labill.
In its assessment, the HMPC considered the results of laboratory tests as well as studies in patients looking in particular at the effects of a component of eucalyptus leaf, called 1,8 cineole (also known as eucalyptol). 
Odbor HMPC je v svoji oceni proučil rezultate laboratorijskih preskusov ter študij pri bolnikih, pri čemer se je osredotočal zlasti na učinke sestavine lista evkaliptusa, ki se imenuje 1,8 cineol (znan tudi pod imenom evkaliptol).
This summary is not intended to provide practical advice on how to use medicines containing eucalyptus leaf. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo list evkaliptusa.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of eucalyptus leaf. 
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo lista evkaliptusa.
Further information on the risks associated with eucalyptus leaf medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo list evkaliptusa, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
The HMPC recommended that eucalyptus leaf medicines should not be used in children under 30 months of age because of the risk of laryngospasm (contraction of the vocal cords). 
Odbor HMPC je priporočil, da se zdravil, ki vsebujejo list evkaliptusa, ne sme uporabljati pri otrocih, mlajših od 30 mesecev, zaradi tveganja za laringospazem (krč glasilk).
Comminuted preparations of eucalyptus leaf should only be used in adults and children over the age of 12 years, while tincture preparations should only be used in adults due to high content of ethanol (pure alcohol). 
Zdrobljeni pripravki lista evkaliptusa se lahko uporabljajo samo pri odraslih in otrocih, starejših od 12 let, pripravki tinkture pa zaradi visoke vsebnosti etanola (čistega alkohola) samo pri odraslih.
Preparations from dried eucalyptus leaf are obtained by comminuting (reducing into tiny pieces) the dried leaves of older branches of the tree, or by using them to produce a tincture (an alcoholic extract of the plant material). 
Pripravki iz posušenih listov evkaliptusa se pridobivajo z drobljenjem (zmanjšanjem na zelo majhne dele) suhih listov starejših vej drevesa ali pa se jih uporabi za izdelavo tinkture (alkoholnega izvlečka rastlinskega materiala).
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing eucalyptus leaf. 
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo list evkaliptusa.
The HMPC conclusions on the use of eucalyptus leaf medicines for the relief of cough associated with a cold are based on their ‘traditional use' in this condition. 
Zaključki odbora HMPC o uporabi zdravil, ki vsebujejo list evkaliptusa in se uporabljajo za lajšanje kašlja pri prehladu, temeljijo na njihovi tradicionalni uporabi pri tem stanju.
Herbal medicines containing eucalyptus leaf are usually available as comminuted herbal material for the preparation of a herbal tea to be drunk, an infusion to be inhaled or a liquid to be taken by mouth. 
Zdravila rastlinskega izvora, ki vsebujejo list evkaliptusa, so navadno na voljo kot zdrobljen rastlinski material za pripravo zdravilnega čaja, ki se ga pije, prevretka, ki se ga inhalira, ali tekočine, ki se jo jemlje peroralno (zaužije skozi usta).
Any applications for the licensing of medicines containing eucalyptus leaf have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. 
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo list evkaliptusa, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
Information on the use and licensing of eucalyptus leaf medicines in EU Member States should be obtained from the relevant national authorities. 
Za informacije o uporabi in dovoljenjih za promet z zdravili, ki vsebujejo list evkaliptusa, v državah članicah EU se obrnite na pristojni nacionalni organ.
Further information on the HMPC assessment of eucalyptus leaf medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o oceni zdravil, ki vsebujejo list evkaliptusa, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
The HMPC concluded that, on the basis of its long-standing use, eucalyptus leaf can be used for the relief of cough associated with a cold. 
Odbor HMPC je na osnovi dolgoletne uporabe lista evkaliptusa zaključil, da se ga lahko uporablja za lajšanje kašlja pri prehladu.
For more information about treatment with eucalyptus leaf medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravili, ki vsebujejo list evkaliptusa, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
How are eucalyptus leaf medicines approved in the EU? 
Kako so zdravila, ki vsebujejo list evkaliptusa, odobrena v EU?
Other information about eucalyptus leaf medicines 
Druge informacije o zdravilih, ki vsebujejo list evkaliptusa
What evidence supports the use of eucalyptus leaf medicines? 
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo list evkaliptusa?
What are the risks associated with eucalyptus leaf medicines? 
Kakšna tveganja so povezana z zdravili, ki vsebujejo list evkaliptusa?
What is eucalyptus leaf? 
Kaj je list evkaliptusa?
For practical information about using eucalyptus leaf medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist. 
Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
Detailed instruction on how to take eucalyptus leaf medicines and who can use them can be found in the package leaflet that comes with the medicine. 
uporabi zdravil, ki vsebujejo list evkaliptusa, in o tem, kdo jih lahko uporablja, so na voljo v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
Eucalyptus leaf can also be found in combination with other herbal substances in some herbal medicines. 
List evkaliptusa je v nekaterih zdravilih rastlinskega izvora lahko na voljo tudi v kombinaciji z drugimi rastlinskimi snovmi.Ta povzetek teh kombinacij ne vključuje.
Committee on Herbal Medicinal Products (HMPC) 
EMA/HMPC/300235/2013 Odbor za zdravila rastlinskega izvora (HMPC)
1 bottle + 1 measuring spoon 
1 plastenka + merilna žlička
Package size mg/ml 
EU/1/06/343/005 Baraclude 0,05 mg/ml Peroralna raztopina
You will hear a click. 
Zaslišali boste klik.
26 July 2018 
26. julij 2018
Both -2.5 
obe -2,5
Elderly (aged 65 years and over) 
Starejši (stari 65 let ali več)
There may be local regulations for disposal. 
Morda obstajajo lokalni predpisi za odstranjevanje.
Of these, more than 1,300 patients were exposed for at least 12 months. 
Med njimi je bilo več kot 1.300 bolnikov izpostavljenih zdravilu najmanj 12 mesecev.
The injection could take about 15 seconds. 
Injiciranje naj traja približno 15 sekund.
- Then contact your doctor, who will tell you when you should schedule your next dose. 
- Nato obvestite svojega zdravnika, ki vam bo povedal, za kdaj morate načrtovati naslednji odmerek.
Contact your doctor immediately. 
Takoj obvestite zdravnika.
No safety data are available in these patients. 
O teh bolnikih ni na voljo nobenih varnostnih podatkov.
The safety and efficacy of Aimovig in children below the age of 18 years have not yet been established. 
Varnost in učinkovitost zdravila Aimovig pri otrocih, starih manj kot 18 let, še nista bili dokazani.
Press the start button. 
Pritisnite sprožilni gumb.
Approximately 41% of patients in the study had medication overuse. 
Približno 41 % bolnikov v študiji je prekomerno uporabljalo zdravila.
Biotransformation / Elimination 
Biotransformacija/izločanje
Possible side effects are listed below. 
Možni neželeni učinki so našteti spodaj.
59% of patients completing the study achieved a 50% response in the last month of the study. 
Med bolniki, ki so zaključili študijo, jih je 59 % doseglo 50-odstotni odziv v zadnjem mesecu študije.
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. 
Za izboljšanje sledljivosti bioloških zdravil je treba jasno zabeležiti ime in številko serije danega zdravila.
The injections can also be given by another individual who has been appropriately instructed. 
Injekcije lahko bolniku daje tudi druga oseba, ki se je za to ustrezno usposobila.
Treatment should be initiated by physicians experienced in the diagnosis and treatment of migraine. 
Zdravljenje naj uvedejo zdravniki, ki imajo izkušnje z diagnostiko in zdravljenjem migrene.
Talk to your doctor or pharmacist about proper disposal. 
Z zdravnikom ali farmacevtom se posvetujte o pravilnem odstranjevanju.
If you have not noticed any treatment effect after 3 months, tell your doctor who will decide whether you should continue treatment. 
Če po treh mesecih ne opazite nobenega učinka zdravljenja, povejte zdravniku, ki bo odločil, ali je z zdravljenjem treba nadaljevati ali ne.
Less than 2% of patients in these studies discontinued due to adverse events. 
V teh študijah je manj kot 2 % bolnikov prekinilo zdravljenje zaradi neželenih učinkov.
Evaluation of the need to continue treatment is recommended regularly thereafter. 
Po preteku tega obdobja je priporočeno redno ocenjevanje potrebe po nadaljnjem zdravljenju.
It has biological activity in cynomolgus monkeys, but this species is not an appropriate model for evaluation of tumorigenic risk. 
Biološko aktivnost izkazuje pri opicah cinomolgus, vendar ta vrsta ne predstavlja ustreznega modela za oceno tveganja za tumorigenost.
Do not use Aimovig: - if you are allergic to erenumab or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Aimovig: - če ste alergični na erenumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
See section “Injection site reactions” below. 
Glejte poglavje “Reakcije na mestu injiciranja” spodaj.
In the event of an overdose, the patient should be treated symptomatically and supportive measures instituted as required. 
V primeru prevelikega odmerjanja je priporočeno bolnika zdraviti simptomatsko in po potrebi uvesti ukrepe podpornega zdravljenja.
Consideration should be given to discontinuing treatment in patients who have shown no response after 3 months of treatment. 
O prekinitvi zdravljenja je treba razmisliti pri bolnikih, pri katerih po 3 mesecih zdravljenja ne pride do odziva.
Do not give this medicine to children or adolescents (under 18 years old) because the use of Aimovig has not been studied in this age group. 
Zdravila Aimovig ne smete dajati otrokom ali mladostnikom (mlajšim od 18 let), ker uporabe tega zdravila pri navedeni starostni skupini niso raziskali.
The injection must be administered within 5 minutes. 
Zdaj morate zdravilo injicirati v roku 5 minut.
Clean the injection site with an alcohol wipe and let the skin dry. 
Mesto injiciranja očistite z alkoholnim zložencem in pustite, da se koža posuši.
Some patients may benefit from a dose of 140 mg every 4 weeks (see section 5.1). 
Nekaterim bolnikom lahko koristi odmerek140 mg enkrat na vsake 4 tedne (glejte poglavje 5.1).
Follow the new schedule exactly as your doctor has told you. 
Upoštevajte novi razpored točno tako, kot vam naroči zdravnik.
Clinical studies have demonstrated that the majority of patients responding to therapy showed clinical benefit within 3 months. 
V kliničnih študijah se je pokazalo, da je pri večini bolnikov z odzivom na zdravljenje prišlo do kliničnih koristi v 3 mesecih.
Two elimination phases were observed for erenumab. 
Pri erenumabu so opažali dve fazi izločanja.
79.8% completed the entire study out to 52 weeks. 
79,8 % bolnikov je zaključilo celotno študijo do konca 52. tedna.
It belongs to a group of medicines called monoclonal antibodies. 
Sodi v skupino zdravil, ki jih imenujemo monoklonska protitelesa.
Note: When the injection is completed, the window will turn yellow and you may hear a second click. 
Opozorilo: ko se injiciranje zaključi, se okence obarva rumeno in lahko zaslišite drugi klik.
Pharmacotherapeutic group: Analgetics, antimigraine preparations, ATC code: N02CX07 
Farmakoterapevtska skupina: analgetiki, zdravila proti migreni, oznaka ATC: N02CX07
Demographics and baseline disease characteristics were balanced and comparable between study arms. 
Demografske značilnosti in osnovne značilnosti bolezni so bile med študijskimi skupinami enakomerno razporejene in primerljive.
114 cases were received from postmarketing sources and 3 from clinical trials. 
114 primerov izhaja iz izkušenj po prihodu zdravila na trg, 3 pa iz kliničnih študij.
Inhibition of the effects of CGRP could theoretically attenuate compensatory vasodilation in ischaemic-related conditions. 
Zaviranje delovanja CGRP bi teoretično lahko zmanjšalo kompenzacijsko vazodilatacijo pri boleznih z ishemijo.
Overall, 39% had failed one or more previous prophylactic pharmacotherapies due to lack of efficacy or poor tolerability. 
Skupno je pri 39 % prišlo do neuspeha z eno ali več predhodnih profilaktičnih farmakoterapij zaradi nezadostne učinkovitosti ali slabega prenašanja.
It is unknown whether erenumab is excreted in human milk. 
Ni znano, ali se erenumab izloča v materino mleko.
Efficacy was sustained up to 1 year in the active re-randomisation part of Study 2. 
Učinkovitost se je ohranjala do 1 leto v delu Študije 2 z aktivnim zdravljenjem po ponovni randomizaciji.
Afterwards, use of Aimovig could be considered during breast-feeding only if clinically needed. 
Kasneje je mogoče razmisliti o uporabi zdravila Aimovig med dojenjem, če je to klinično potrebno.
Patients with certain major cardiovascular diseases were excluded from clinical studies (see section 5.1). 
Bolniki z določenimi pomembnimi srčno-žilnimi boleznimi niso bili vključeni v klinične študije (glejte poglavje 5.1).
CI = confidence interval; MMD = monthly migraine days; HIT-6 = Headache Impact Test; MIDAS = Migraine Disability Assessment a 
IZ = interval zaupanja; MDM = število migrenskih dni na mesec; HIT-6 = vprašalnik o vplivu glavobola (Headache Impact Test); MIDAS = vprašalnik za oceno onesposobljenosti zaradi migrene (Migraine Disability Assessment); NP = vrednost ni podana a
There are a limited amount of data from the use of erenumab in pregnant women. 
Podatki o uporabi erenumaba pri nosečnicah so omejeni.
If it is stored at a higher temperature or for a longer period it must be discarded. 
Če je bilo zdravilo shranjeno pri višji temperaturi ali dalj časa, ga morate zavreči.
Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. 
Znano je, da se humani imunoglobulini G izločajo v materino mleko v prvih nekaj dneh po porodu, kmalu nato pa se njihova koncentracija zniža na nizko raven, vendar iz tega razloga tveganja za dojenega otroka v tem kratkem obdobju ni mogoče izključiti.
Patients had a median age of 43 years, 83% were female and 94% were white. 
Mediana starost bolnikov je bila 43 let, 83 % je bilo žensk in 94 % je bilo belcev.
Your doctor or nurse will give you or your caregiver training in the right way to prepare and inject Aimovig. 
Vaš zdravnik ali medicinska sestra bosta vas ali vašega negovalca ustrezno usposobila, da boste znali pripraviti in injicirati zdravilo Aimovig.
The mutagenic potential of erenumab has not been evaluated; however, monoclonal antibodies are not expected to alter DNA or chromosomes. 
Mutagenega potenciala erenumaba niso ocenjevali, a monoklonska protitelesa predvidoma ne spreminjajo strukture DNK in kromosomov.
In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000). 
Pri tem ustrezna kategorija pogostnosti posameznega neželenega učinka temelji na naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki
If you forget to use Aimovig - If you forget an Aimovig dose, take it as soon as possible after you realise. 
Če ste pozabili uporabiti zdravilo Aimovig - Če ste si pozabili dati odmerek zdravila Aimovig, si ga odmerite čimprej po tem, ko to ugotovite.
Talk to your doctor before using Aimovig: - if you have ever had an allergic reaction to rubber latex. 
Pred začetkom uporabe zdravila Aimovig se posvetujte z zdravnikom: - če ste že kdaj imeli alergijsko reakcijo na lateks iz kavčuka.
Differences from placebo were observed from Month 1 onwards. 
Razliko v primerjavi z uporabo placeba so opažali od 1. meseca dalje.
d p value is calculated based on the odds ratios. 
Vrednost p je izračunana na osnovi razmerij obetov (OR-odds ratio).
For the secondary endpoints, all p-values are reported as unadjusted p-values and are statistically significant after adjustment for multiple comparisons. 
Za sekundarne cilje študije so vse vrednosti p podane kot neprilagojene vrednosti p in so statistično značilne po prilagajanju na multiple primerjave.
Use Aimovig exactly as prescribed by your doctor. 
Zdravilo Aimovig uporabljajte natančno tako, kot vam predpiše zdravnik.